| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
24,454 |
22,055 |
$2.24M |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
16,556 |
15,929 |
$1.52M |
| S9083 |
Global fee urgent care centers |
14,326 |
12,628 |
$1.22M |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
8,986 |
8,723 |
$686K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
6,987 |
6,234 |
$534K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,588 |
3,298 |
$431K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
3,107 |
2,954 |
$355K |
| 99201 |
|
52 |
52 |
$4K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
66 |
62 |
$4K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
10,419 |
9,586 |
$2K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
13,356 |
12,199 |
$2K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
11,252 |
10,035 |
$2K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
16,580 |
8,544 |
$689.67 |
| 81003 |
|
1,791 |
1,721 |
$95.00 |
| 87430 |
|
850 |
755 |
$48.00 |
| 93000 |
|
422 |
379 |
$47.03 |
| 73630 |
|
169 |
120 |
$31.44 |
| 71046 |
Radiologic examination, chest; 2 views |
215 |
172 |
$30.42 |
| 81025 |
|
2,596 |
2,413 |
$15.27 |
| 81002 |
|
2,531 |
2,320 |
$12.38 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
17 |
15 |
$11.50 |
| 73610 |
|
253 |
212 |
$0.00 |
| 73130 |
|
104 |
88 |
$0.00 |
| 73110 |
|
36 |
27 |
$0.00 |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
13 |
13 |
$0.00 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
2,551 |
2,329 |
$0.00 |
| 73562 |
|
35 |
27 |
$0.00 |
| 69210 |
|
56 |
40 |
$0.00 |
| 73140 |
|
14 |
13 |
$0.00 |
| 90714 |
|
14 |
12 |
$0.00 |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
280 |
274 |
$0.00 |
| 99000 |
|
103 |
97 |
$0.00 |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
125 |
124 |
$0.00 |
| 99070 |
|
43 |
43 |
$0.00 |
| 86308 |
|
30 |
29 |
$0.00 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
29 |
24 |
$0.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
32 |
27 |
$0.00 |
| 86769 |
|
128 |
128 |
$0.00 |